Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Table 3

In vitro activity of fosfomycin against aerobic and facultative Gram-negative bacteria (cumulative data from [13, 29, 31–35]).

Organism	Number of isolates tested	Fosfomycin
		MIC50 (µg/mL)	MIC90 (µg/mL)	Range (µg/mL)
Acinetobacter spp.	244	128	128–512	0.25–512
Citrobacter spp. (C. diversus, C.freundii, and C. koseri)	437	0.5–2	1–4	≤0.12–64
Enterobacter spp. (E. agglomerans, E. aerogenes, and E. cloacae)	808	8–32	16–256	0.25–>512
Escherichia coli	7735	0.5–4	1–16	0.25–512
Escherichia coli ESBL-producing	296	2	4	≤1–512
Escherichia coli AmpC-producing	135	2	4–16	≤1–>512
Haemophilus influenzae	50	1	4	1–128
Klebsiella oxytoca	153	8	16–32	1–64
Klebsiella pneumoniae	284	4–16	16–128	≤2–512
Klebsiella spp.	788	16	32–128	≤2–512
Morganella morganii	59	128–256	512	8–>512
Proteus mirabilis	1533	1–4	8–64	≤0.12–>512
Proteus vulgaris (indole-positive Proteus)	431	≤2–16	8–256	0.5–256
Providencia spp. (P. rettgeri and P. stuartii)	164	2–16	8–128	≤2–512
Pseudomonas aeruginosa	1450	32–64	64–128	2–>512
Pseudomonas spp.	35	128	256	≤0.5–512
Serratia marcescens	383	8	16–32	0.5–128
Shigella spp.	185	2	2	0.5–64
Stenotrophomonas maltophilia	151	64–128	128	16–512